Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis - Top-Institutions - MDSpire

Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis

  • By

  • Jingqiang Xie

  • Chunying Pu

  • Mingyue Sun

  • July 3, 2026

  • 0 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    Yale University School of Medicine / Yale New Haven Psychiatric Hospital
    Yale University School of Medicine / Yale New Haven Psychiatric Hospital

    New Haven, Connecticut

    Key Differentiators

    • Psychiatry

  • #2

    University of Pennsylvania, Perelman School of Medicine
    University of Pennsylvania, Perelman School of Medicine

    Philadelphia, Pennsylvania

    Key Differentiators

    • Psychiatry

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Psychiatry

  • #4

    OM1 Mental Health Specialty Network
    OM1 Mental Health Specialty Network

    Remote, N/A

    Key Differentiators

    • Mental Health

  • #5

    Medical University of Gdańsk
    Medical University of Gdańsk

    Gdańsk, Poland

    Key Differentiators

    • Psychiatry

Original Source(s)

Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis

  • by Jingqiang Xie, Chunying Pu, Mingyue Sun

  • July 3, 2026

Related Content

Republican Tom Kean Jr. reveals depression diagnosis after his four-month absence from Congress

Development and validation of a prediction model for psychological distress in patients with differentiated thyroid cancer undergoing ¹³¹I therapy

Elevated NHHR at admission is independently associated with elevated post-stroke depressive symptoms